VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Monday. The brokerage issued a sell rating on the stock.

Separately, Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a report on Friday, August 16th.

VolitionRx Price Performance

VNRX stock opened at $0.63 on Monday. The company has a market capitalization of $58.02 million, a P/E ratio of -1.57 and a beta of 1.10. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23. The firm’s fifty day simple moving average is $0.68 and its 200-day simple moving average is $0.69.

VolitionRx (NYSE:VNRX) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.34 million. As a group, sell-side analysts forecast that VolitionRx will post -0.31 earnings per share for the current year.

Insider Buying and Selling

In other VolitionRx news, Director Guy Archibald Innes bought 150,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were purchased at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the transaction, the director now directly owns 406,683 shares of the company’s stock, valued at approximately $272,477.61. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 12.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities & Exchange Commission. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.